Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

INSIDE INFORMATION
ANNOUNCEMENT OF ESTIMATED INTERIM RESULTS FOR 2026

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to the disclosure obligations under Rule 13.09(2)(a) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company sets out in this announcement the financial data of the Group for the six months ended June 30, 2026. Such data are prepared in accordance with the China Accounting Standards for Business Enterprises and are preliminary accounting data only and have not been audited by an accounting firm. The data set out in this announcement may differ from the final data to be disclosed in the interim report of the Company. Shareholders and investors of the Company are advised to exercise caution when dealing in the shares of the Company.

I. ESTIMATED RESULTS FOR THE PERIOD

(I) Period of estimated results

From January 1, 2026 to June 30, 2026.

(II) Estimated results

1. Based on the preliminary calculations by the finance department of the Company, it is expected that the Group's revenue for the first half of 2026 will be ranging from RMB936,388,600 to RMB946,388,600, representing an increase of RMB315,425,400 to RMB325,425,400 as compared with the corresponding period of last year, or a period-on-period increase of 50.80% to 52.41%.

2. It is expected that the net profit attributable to owners of the Company for the first half of 2026 will be ranging from RMB236,094,400 to RMB246,094,400, representing an increase of RMB188,095,300 to RMB198,095,300 as compared with the corresponding period of last year, or a period-on-period increase of 391.87% to 412.71%.

3. It is expected that the net profit attributable to owners of the Company after deducting non-recurring profit or loss for the first half of 2026 will be ranging from RMB192,445,800 to RMB202,445,800, representing an increase of RMB163,893,700 to RMB173,893,700 as compared with the corresponding period of last year, or a period-on-period increase of 574.02% to 609.04%.

(III) This estimated results announcement has not been audited by a certified public accountant.

II. RESULTS AND FINANCIAL CONDITIONS FOR THE CORRESPONDING PERIOD OF LAST YEAR

1. Revenue: RMB620,963,200.

2. Total profit: RMB59,619,600.

3. Net profit attributable to owners of the Company: RMB47,999,100.

4. Net profit attributable to owners of the Company after deducting non-recurring profit or loss: RMB28,552,100.

5. Earnings per share: RMB0.12.

III. MAIN REASONS FOR THE CHANGES IN RESULTS FOR THE PERIOD

(I) As the biopharmaceutical industry enters a new phase defined by innovation-driven growth, the Company has fully unleashed its competitive advantages relying on its forward-looking R&D layout, leading products and high-quality services, as well as a premium customer network covering top global pharmaceutical companies and leading biotechnology companies to deeply capitalize on the business development opportunities brought by the industry's improving prosperity. During the reporting period, the Company achieved dual-engine growth and leapfrog synergy across its two major business lines, driving sustained rapid growth in revenue.

(II) Building upon the significant increase in the Company's revenue scale and industry position, the economies of scale in terms of the Company's production capacity and operations accelerated to materialize. On this basis, coupled with the ongoing deepening of lean management, the Company has effectively achieved cost reduction and efficiency enhancement, driving a further increase in the overall gross profit margin and an effective reduction in the expense ratio for the period. As a result, the Company's profitability has been significantly strengthened, and scaled profits are being realized at an accelerated pace.

IV. RISK WARNING

This estimated results announcement is based on the preliminary calculations made by the finance department of the Company based on its own professional judgment and has not been audited by a certified public accountant. There are no material uncertainties affecting the accuracy of the contents of this estimated results announcement.

V. OTHER MATTERS

The above estimated data are only preliminary accounting data. For specific and accurate financial data, please refer to the 2026 interim report to be officially disclosed by the Company. Investors are advised to pay attention to investment risks.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, August 6, 2026

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian as executive Director; Dr. Zhou Kexiang, Ms. Zhang Leidi and Dr. Liu Hongkang as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors; and Ms. Li Yan as employee Director.